The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
The kidney care provider has established over 40 dialysis centres, delivering more than 40,000 dialysis sessions
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
The new unit is expected to serve thousands of patients annually, helping address a critical gap in dialysis access
New Yamuna Vihar facility to train 40 students annually through diploma-led, hands-on renal care education
The new single-pill therapy combines cilnidipine, telmisartan and metoprolol, bringing together three established antihypertensive agents with complementary mechanisms
Subscribe To Our Newsletter & Stay Updated
